
    
      The study will consist of a 12 month, open-label, randomized, active controlled, parallel
      group study comparing the efficacy and safety of weekly MOD-4023 to daily growth hormone
      (GH), Genotropin. After 12 months, subjects will have the option to enter the long term
      open-label extension.
    
  